个人简历

1993年6月毕业于四川大学化学系物理化学专业，获硕士学位。2002年至今任四川大学华西药学院副教授、硕士生导师。四川省卫生厅学术技术带头人后备人选。已在J Med Chem, Arch Pharm Res, J Pharm Sci-US, Bioorg Med Chem Lett等国内外学术期刊发表SCI论文50余篇。获授权专利3项，获软件著作权4项。编写《物理化学》、《药物现代评价方法》等教材。主持国家自然科学基金面上项目2项、“十三五”科技重大专项课题1项等。获2015年教育部科技进步奖（自然科学类）一等奖。

研究领域

1.药物新剂型与新制剂研究 2.新药的研究与开发

近期论文

1.Qi-Zheng Sun#, Gui-Feng Lin#, Lin-Li Li#, Xi-Ting Jin, Lu-Yi Huang, Guo Zhang, Rong Xiang, Chong Chen, Yu-Quan Wei, Guang-Wen Lu, and Sheng-Yong Yang. Discovery of Potent and Selective Inhibitors of Cdc2-like Kinase 1 (CLK1) as a New Class of Autophagy Inducers. J Med Chem. 2017, 60 (14): 6337–6352. 2.Lei Zhong, Jiao Yang, Zhixing Cao, Xin Chen, Yiguo Hu, Linli Li*, and Shengyong Yang*. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget. 2017, 8(8): 12843–12854. 3.Xiaoai Wu, Zhen Fang, Bo Yang, Lei Zhong, Qiuyuan Yang, Chunhui Zhang, Shenzhen Huang, Rong Xiang, Takayoshi Suzuki, Lin-Li Li*, Sheng-Yong Yang*. Discovery of KDM5A Inhibitors: Homology Modeling, Virtual Screening and Structure-Activity Relationship Analysis. Bioorg Med Chem Lett. 2016, 26: 2284-2288. 4.Chun-Hui Zhang#, Kai Chen#, Yan Jiao#, Lin-Li Li#, Ya-Ping Li, Rong-Jie Zhang, Ming-Wu Zheng, Lei Zhong, Shen-Zhen Huang, Chun-Li Song, Wan-Ting Lin, Jiao Yang, Rong Xiang, Bing Peng, Jun-Hong Han, Guang-Wen Lu, Yu-Quan Wei, and Sheng-Yong Yang. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d] pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. J Med Chem. 2016, 59 (21): 9788–9805. 5.Xing-Dong Lin, Hui-Wen Yang, Shuang Ma, Wei-Wei Li, Chun-Hui Zhang, Wen-Jing Wang, Rong Xiang, Lin-Li Li*, and Sheng-Yong Yang*. Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. Bioorg Med Chem Lett. 2015, 25: 4534-4538. 6.杨 波, 汪文静, 李琳丽*. 小分子共价抑制剂研究进展. 药学学报. 2014, 49: 158-165. 7.Huan-Zhang Xie, Hai Lan, You-Li Pan, Jun Zou, Ze-Rong Wang, Lin-Li Li*. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common-feature pharmacophore model derived from known ligands crystallized with ALK. Chem Biol Drug Des. 2013, 81: 175-184. 8.Lei Di-Wu, Lin-Li Li*, Wen-Jing Wang, Huan-Zhang Xie, Jiao Yang, Chun-Hui Zhang, Qi Huang, Lei Zhong, Shan Feng, Sheng-Yong Yang*. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking. J Mol Graph Model. 2012, 36: 42-47. 9.Lei Zhong, Chang-Ying Ma, Hui Zhang, Li-Jun Yang, Hua-Lin Wan, Qing-Qing Xie, Lin-Li Li*, Sheng-Yong Yang*. A prediction model of substratesand non-substrates of breast cancer resistance protein (BCRP) developed byGA-CG-SVM method. Comput Biol Med. 2011, 41: 1006-1013. 10.Qi Huang, Lin-Li Li, Sheng-Yong Yang*. PhDD: A new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility. J Mol Graph Model. 2010, 28: 775-787.